What's Going On With Biohaven Stock Wednesday?
What's Going On With Biohaven Stock Wednesday?
Biohaven Ltd. (NYSE:BHVN) stock is moving lower Wednesday. The company recently presented several updates in different fields such as immunology and oncology at its Annual Investor Research and Development Day.
Biohaven Ltd.（纽约证券交易所代码：BHVN）股价周三走低。该公司最近在其年度投资者研发日上发布了免疫学和肿瘤学等不同领域的几项最新消息。
The Details: The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two different studies and presented other updates.
详情：该公司宣布为患者服用了某些癌症的新可能治疗方法，展示了来自两项不同研究的阳性数据，并介绍了其他最新情况。
Biohaven started the first patient's treatment in a Phase 1/2 trial for BHV-1510 which includes subjects with select advanced or metastatic epithelial cell tumors.
Biohaven 在 BHV-1510 的 1/2 期试验中开始了第一位患者的治疗，该试验包括患有特定晚期或转移性上皮细胞肿瘤的受试者。
In addition, Biohaven has entered into a agreement with Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) where Biohaven will finance the planned clinical trial and Regeneron will provide Libtayo allowing the companies to explore the combination of BHV-150 and Libtayo.
此外，Biohaven已与Regeneron Pharmicals, Inc.（纳斯达克股票代码：REGN）签订协议，由Biohaven为计划中的临床试验提供资金，Regeneron将向Libtayo提供Libtayo，允许两家公司探索 BHV-150 和Libtayo的组合。
"We are extremely proud to advance our first oncology clinical program with a potentially best in class ADC [Antibody Drug Conjugate]," said Nushmia Khokhar, M.D., chief medical officer of oncology at Biohaven.
Biohaven肿瘤学首席医学官努什米亚·霍哈尔医学博士说：“我们非常自豪能够使用可能处于同类最佳的ADC（抗体药物偶联物）来推进我们的第一个肿瘤学临床项目。”
"With the initiation of this monotherapy study, we are one step closer to providing differentiated and superior treatment options to people living with cancer. We are also excited to work with Regeneron and efficiently explore BHV-1510 in combination with its PD-1 inhibitor Libtayo across a range of tumors."
“随着这项单一疗法研究的启动，我们离为癌症患者提供差异化和卓越的治疗选择又近了一步。我们也很高兴能与 Regeneron 合作，高效地探索 BHV-1510 与其 PD-1 抑制剂的组合 Libtayo 跨越一系列肿瘤。”
Biohaven released positive Phase 1 data regarding BHV-8000 including positive regulatory input, allowing the start of programs aiming to prevent amyloid-related imaging abnormalities associated with certain medications and Parkinson's disease.
Biohaven 发布了有关 BHV-8000 的阳性 1 期数据，包括积极的监管意见，这使旨在预防与某些药物和帕金森氏病相关的淀粉样蛋白相关影像学异常的计划得以启动。
Biohaven started five new clinical trials with BHV-7000 which is aimed at targeting two types of epilepsy, bipolar disorder, and major depressive disorder.
Biohaven 开始了五项新的 BHV-7000 临床试验，旨在针对两种类型的癫痫、双相情感障碍和重度抑郁症。
Also, the company reported positive interim data from its ongoing Phase 1 study of BHV-1300 focused on investigating a new drug. Biohaven anticipates to have Myostatin program data for Phase 3 spinal muscular atrophy in the second half of 2024.
此外，该公司报告了正在进行的 BHV-1300 第一期研究的积极中期数据，该研究的重点是研究一种新药。Biohaven预计将在2024年下半年获得3期脊髓性肌萎缩症的肌抑素计划数据。
Related Link: Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics
相关链接：破解密码：了解分析师对Sage Therapeutics的评论
BHVN Price Action: Biohaven shares are trading 18.9% lower at $30.75 at the time of publication, per data from Benzinga Pro.
BHVN价格走势：根据Benzinga Pro的数据，截至发布时，Biohaven股价下跌18.9％，至30.75美元。
Image: Akava Photo from Pixabay
图片：来自 Pixabay 的 Akava 照片